Bacterial sepsis is a life-threatening condition that arises when the body’s response to an infection injures its tissues and organs. Sepsis has recently been re-defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis, as a medical condition, was first introduced by Hippocrates (460 through 470 BC), and is derived from the Greek word sipsi, i.e., “to make rotten.” This disease entity has had many iterations since that time, with the foundations for the modern understanding of sepsis coming about through breakthroughs in the late 19 century. The development of antiseptic measures, the germ theory of disease, and bacteriology lead to the widely held belief that sepsis was a systemic infection resulting from a pathogenic organism invading the host that spreads via the bloodstream (i.e., septicemia). It was not until the further widespread use of antibiotics and the discovery of endotoxin that suggested the pathophysiology of sepsis was far more complex.
Despite the increased understanding of this complex disease process, mortality from sepsis remains the most common cause of death in the non-coronary intensive care unit. In the hopes of allowing earlier therapeutic intervention, an international consensus meeting in 1991, created and defined terms, such as systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock (known now as Sepsis-1). SIRS describes the inflammatory process, independent of cause based on a combination of vital signs and blood work.
SIRS includes 2 or more of the following:
Multi-Organ Dysfunction Syndrome
Multi-organ dysfunction syndrome (MODS) is the presence of altered organ function in an acutely ill patient such that homeostasis cannot be maintained without intervention.
Sepsis-3 redefined sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to infection. It is importantly noted that not all patients that present with SIRS have an infection, as well, not all patients who have an infection are septic. Sepsis is differentiated from infection by a dysregulated host response and the presence of end-organ dysfunction. Sepsis and its sequelae represent a continuum of clinical and pathophysiologic severity, resulting in progressive physiologic failure of several inter-dependent organ systems.
The Surviving Sepsis Campaign (SSC) and its accompanying treatment bundle were developed with the intention of rapid identification and treatment of septic patients. In 2001, Rivers et al. showed the benefits of a specific protocol termed early goal-directed therapy (EGDT) versus standard therapy, with a resulting significant decrease in mortality. EGDT was subsequently incorporated into the first iteration of the 6hr resuscitation bundle of the Surviving Sepsis Campaign guidelines. These guidelines have changed since their first publication with revisions in 2008, 2012, and finally 2016. Heightened scrutiny of these guidelines and recommendations was the result of the Centers for Medicare and Medicaid Services(CMS) using the bundled care as a hospital quality measure. These were initially adopted by the National Quality Forum 0-500 and subsequently became the Sepsis CMS Core measures known as SEP-1. These measures have come under criticism primarily for the assumption that bundled and structured care is superior to individualized treatment guided by the bedside clinician. In addition to the numerous criticisms of the measures or the evidence supporting them, their mortality benefit remains a point of controversy for many clinicians.
The inflammatory response that leads to clinical syndromes such as sepsis is triggered by conditions that threaten the functional integrity of the host, in this case, microbial invasion. Both pro-inflammatory responses and anti-inflammatory responses characterize the host response. The extent of this process depends entirely on both pathogen factors (load, virulence, and pathogen-associated molecular pattern) and host factors (environment, genetics, age, other illnesses, and medications).
At its onset, the host cell will recognize the pathogen leading to a perpetuation of inflammation starting with leukocyte activation then complement activation and coagulation activation, ultimately resulting in necrotic cell death. Normally, leukocyte activation, primarily neutrophils, are activated early in the inflammatory response cycle and undergo a respiratory burst, consuming lots of oxygen with the goal of creating toxic metabolites of oxygen. Neutrophils also use their myeloperoxidase enzyme to convert hydrogen peroxide to hypochlorite, a powerful germicidal agent (the active ingredient in bleach). These metabolites are stored in cytoplasmic granules and are released during neutrophil degranulation. This necrotic cell death releases further toxic metabolites which causes further inflammatory pathway activation and further collateral tissue damage. This cascade can become a self-sustaining process if left unchecked.
Pro-inflammatory mechanisms are kept in check by the immune system via the humoral, cellular and neural mechanisms. Regulation by the humoral mechanism is characterized by an impaired function of immune cells with the expansion of regulatory T cells and myeloid suppressor cells that further reduce inflammation. Regulation by the neural mechanism involves the hypothalamic-pituitary-adrenal axis and vagus nerve stimulating the spleen to release norepinephrine and acetylcholine secretion by CD4 T cells which helps to suppress the release of pro-inflammatory cytokines. On the cellular level, there is inhibition of pro-inflammatory gene transcription.
The damage inflicted by the inflammatory process is largely due to oxidation, where the production of oxidants overwhelms the body’s endogenous antioxidant defenses. This collateral damage can be the result of inadequate antioxidant protection and is the basis behind newer research geared towards replacing endogenous antioxidants.
Sepsis is associated with high morbidity and mortality and most recently has been identified as affecting nearly 1.7 million US adults every year. Before 2000, mortality was noted to be as high as 50% in severe sepsis and septic shock patients. Even with new technologies and treatments, the mortality remains around 20% to 25% nationwide, with 1 in 3 patients who die in the hospital succumbing to sepsis. Given the reported, increasing prevalence of sepsis, a large amount of importance has been placed on treating and recognizing this disease process early, with the most recent budget reported at around $23.7 billion dollars in 2013.
Sepsis progressing to septic shock and multi-organ failure results from a worsening circulatory insufficiency characterized by hypovolemia, myocardial depression, increased metabolic demands, and vasoregulatory perfusion abnormalities. Classically, septic shock and inflammatory shock have been described as primarily systemic vasodilatation of both arteries and veins. This dilation reduces ventricular preload as well as afterload, by decreasing systemic vascular resistance. The typical hemodynamic pattern in septic shock consists of low cardiac filling pressures, or low central venous pressures (CVP) and low systemic vascular resistance (SVR). With low preload and afterload, cardiac output (CO) must increase to compensate, typically with increased heart rate (CO = Stroke Volume x Heart Rate). This is also why sepsis is thought of as a distributive shock and is also known as hyper-dynamic or warm shock.
The vascular changes resulting in systemic vasodilatation can be attributed in large part to the dysfunction of the vascular endothelium and mitochondria. Part of the inflammatory process can be attributed to the enhanced production of nitric oxide (NO), which is a free radical and is produced in the vascular endothelial cells. In addition to the inflammatory processes, sepsis is also associated with microvascular thrombosis. This is caused by activation of the clotting cascade with tissue factor and exacerbated by decreased anti-coagulation and impaired fibrinolysis. This leads to increased thrombus formation and therefore worsening tissue hypoperfusion. With thrombus formation and tissue hypoperfusion, the vascular endothelial cells also experience a loss of function with cadherin, and tight junctions are disrupted, leading to further capillary leak and increased interstitial edema. To worsen this effect, red blood cells (RBC) have been shown to have decreased deformability during this inflammatory phase and will further contribute to poor tissue oxygenation. Vasodilation, disruption of the vascular endothelium, decreased RBC deformability, with the ensuing hypotension all contribute to worsening tissue oxygenation.
Impaired tissue oxygenation will also cause mitochondrial dysfunction and lead to the shunting of pyruvate away from the Kreb cycle, which when it accumulates will be converted to lactate as a means of continuing metabolism in the critically ill. Hyperlactatemia in sepsis is the result of multiple metabolic adjustments, not simply tissue hypoperfusion. Conditions that are known to favor lactate production include systemic hypoperfusion necessitating anaerobic metabolism, regional hypoperfusion, and microcirculatory dysfunction. Additionally, increased aerobic glycolysis can produce an excess of pyruvate that overwhelms pyruvate dehydrogenase used to take the pyruvate into the Kreb cycle for aerobic metabolism. With the excess pyruvate present, a portion will be shunted to lactate conversion and accumulate in the cytoplasm prior to being dispersed in the bloodstream. This occurs in white blood cells, which rely on anaerobic metabolism especially when activated during periods of infection or inflammation, and have been shown to contribute to increased blood levels of lactic acid. This increased production and decreased clearance of lactate results in hyperlactatemia.
As this disease process progresses, further inflammatory cytokines are released resulting in effects seen in both cardiac activity and splanchnic vasculature. Further depression of cardiac contractility, in both systolic and diastolic phases, is a result of these circulating inflammatory cytokines. Splanchnic blood flow is also affected and primarily shunted to other organs, especially once hypotension is present. This creates an increased risk for translocation of enteric pathogens and endotoxin across the bowel mucosa and into the systemic circulation further aggravating the inciting condition.
Alternatively, this process has been described in terms of oxygen demands and consumption. Sepsis, at its earliest manifestation creates an increased need for oxygen locally, accompanied closely by a critical decrease in systemic oxygen delivery, limiting tissue oxygenation as described via various mechanisms above. This is followed by an increase in the systemic oxygen extraction ratio and an accompanying decrease in central venous oxygen saturation (ScvO2), and mixed venous oxygen saturation (SvO2). When the limits for how much oxygen that can be extracted from blood is reached, cellular metabolism switches to anaerobic metabolism, further contributing to lactate production as noted above. The failure to increase the oxygen extraction ratio and thus increase systemic oxygen consumption is secondary to impairment of microvascular oxygen perfusion as well as mitochondrial dysfunction. This is the basis for following increasing lactate levels or decreasing venous oxygen saturation as a marker for disease severity and prognosis.
The cellular and tissue changes induced by a shock are essentially those also seen in hypoxic injury states. As oxygen tension within the cell decreases, there is a loss of oxidative phosphorylation and decreased generation of ATP. The sodium pump fails, and potassium is lost with concurrent influx of sodium and water, causing the cell to swell in size. With worsening hypoxia, there is a progressive loss of glycogen and decreased protein synthesis. As hypoxic injury continues the cytoskeleton will disperse and “blebs” will appear. Mitochondria will also exhibit swelling at this stage while the endoplasmic reticulum (ER) remains dilated. If oxygen is restored, a lot of these processes and injury can be reversed. If hypoxia persists irreversible injury and cellular necrosis will ensue. Cells at this stage exhibit severe swelling of mitochondria, extensive damage to plasma membranes, and swelling of lysosomes. Cellular death is mainly by necrosis, however, apoptosis also contributes as the mitochondria are believed to leak pro-apoptotic enzymes with swelling. Apoptosis is a pathway of cellular death that is induced by a tightly regulated program that uses its own enzymes to degrade the rest of the cell, in the hopes of limiting collateral tissue damage.
In sepsis, and more specifically septic shock, these changes typically are more evident in tissues that are heavily dependent on blood flow and the elimination of cellular by-products, i.e., brain, heart, lungs, kidneys, adrenals, and gastrointestinal (GI) tract. With respect to the kidneys, biopsies from septic patients reveal a wide range of findings with “non-specific morphologic changes”, not acute tubular necrosis, being the most commonly reported finding. The lungs are another very commonly affected organ in septic shock as it is known to be somewhat resistant to hypoxic injury. However, in septic shock changes of diffuse alveolar damage may develop as a result, notably findings of interstitial and intra-alveolar edema, inflammation, and fibrin deposition. These findings are also associated with the dreaded complication of disseminated intra-vascular coagulation (DIC) which will show further fibrin deposition, as a part of these micro-thrombi, in nearly all the vascular territories of the organs named above. The petechial appearance on the skin, during DIC, is often secondary to the consumption of platelets and clotting factors that are a part of the micro-thrombi. These changes when viewed in isolation are reversible; however, once a patient reaches a state where multiple organ systems are involved, the patient usually dies before they have a chance to recover.
The history and physical exam will vary widely depending on where they fall on the continuum from SIRS to septic shock. Important considerations when taking a history in a patient with suspected sepsis is geared toward assessing those risk factors associated with increased mortality or higher incidence of sepsis as well as inquiring about possible sources of infection. Comorbidities associated with morbidity and mortality in sepsis include active cancer, diabetes, chronic lung disease, congestive heart failure, renal insufficiency, and liver disease(cirrhosis). Age, specifically older than 65 years old, has been shown to be an independent predictor of mortality in sepsis. This is because of the association of increasing age with a decrease in the adaptive immune system with B and T cells showing impaired functionality. Alternatively, gender does not seem to play a role in sepsis mortality as studies focusing on this subject are conflicting. The presence of any of these comorbidities should heighten your suspicion for the patient developing sepsis, and prompt an earlier intervention if possible.
Gathering information geared toward finding an infectious source will help tailor further intervention and management. Notably, a patient’s recent history, hospitalization, and exposure to drug-resistant organisms may help direct what treatment to initiate. Retrospectively, sources of infection have been shown to be in the order of prevalence: pneumonia, intra-abdominal infections, and urinary tract infections. However, the mortality rate is not related to the site of infection or the causative organism, including multi-drug-resistant organisms. Even with this caveat, finding a suspected source of infection is critical in the early stages of a patient’s presentation.
The physical portion of the exam will provide critically important vital signs, allowing for utilization of clinical screening tools. There has been criticism on utilizing the SIRS criteria for this purpose because its specificity in sepsis remains low. However, the basic tenets of observing vital sign abnormalities and systemic response to infection remain valid. The differences and reliability of these clinical scores are discussed in further detail below. Clinical conditions that are associated with inflammatory injury are best grouped as organ systems related to their condition in order of prevalence:
The physical exam should be focused on quickly assessing the patient with initial vitals and if there is suspicion for sepsis, a thorough physical exam looking for a potential infectious source, including a pelvic exam if indicated.
With the increased emphasis placed on earlier detection of sepsis, several clinical scores have been proposed to help further predict which patients are septic and which patients will ultimately have a worse outcome. SIRS, as defined above, has been criticized for being too general, and while being very sensitive, it is also not very specific. The SIRS criteria were developed as a way of identifying this systemic response based on vital signs and lab work, not the source of infection. However, when comparing even newer clinical tools such as the qSOFA score (quick sepsis-related organ failure assessment), the SIRS criteria were still more sensitive. Ultimately, the difficulty in validating and finding a clinical tool that will detect a septic patient 100% of the time is that there is no gold standard for diagnosing sepsis.
To diagnose sepsis in a patient we still rely on three groups of clinical and laboratory data, namely, general systemic manifestations, manifestations of organ dysfunction/failure, and finally, microbiological documentation. The general systemic manifestations are taken into account with the SIRS criteria. Manifestations of organ failure or dysfunction can be seen in changes of platelets, bilirubin, INR, creatinine, and lactic acid among many other surrogate markers. Microbiological documentation includes commonly blood cultures, however they can include urine, peritoneal, synovial, respiratory secretions, and potentially cerebrospinal fluid(CSF). The downside being that in over one-third of clinical cases of sepsis and septic shock the blood cultures are negative, as well contaminants can complicate the picture.
Sepsis-2 Criteria (2001) defined parameters of both physical and laboratory findings present with organ dysfunction, heavily influencing the Surviving Sepsis Campaign and CMS Core Measure (SEP-1). Organ dysfunction as noted in SEP-1, are as follows: SBP less than 90 mm Hg, MAP less than 65 mm Hg, Acute respiratory failure (need for invasive or non-invasive mechanical ventilation), creatinine greater than 2.0, urine output less than 0.5 ml/kg per hour (for 2 consecutive hours), total bilirubin greater than 2 mg/dl, platelet count fewer than 100,000, INR greater than 1.5, or aPTT greater than 60 seconds, or lactate greater than 2 mmol/L. Evaluation for sepsis as the underlying process should be evaluated with these markers of end organ dysfunction in mind.
With a high index of suspicion for sepsis, investigation typically includes:
The treatment and management of sepsis have evolved consistently since it has been recognized as a disease entity. These advances can be credited for the mortality improvement with septic patients that have been seen over the last 2 decades. However, with mortality from sepsis still approaching 20% to 25%, there are improvements still needed to treat and manage these complex patients. Therapies are directed at the basic elements of sepsis as a syndrome of infection, the host response, and organ dysfunction. The initial management of infection requires forming a probable diagnosis, obtaining cultures and initiating appropriate and timely empirical anti-microbial therapy and source control. Attenuating the host response and accompanying organ dysfunction are both parts of ongoing cardio-pulmonary resuscitation.
The initial resuscitation period was previously goal-directed, bundled care, something which the Surviving Sepsis Campaign guidelines promote. Three large trials subsequently have shown no mortality benefit over usual care, which likely reflects the improvement of care, in general, with more of a trend toward early goal-directed therapies. Despite the numerous trials and recommendations evaluating the components of this resuscitation, it remains a subject of debate and the source of ongoing clinical trials. The management, because of its complexities has been grouped into 2 bundles of care, a 3 and 6-hour acute sepsis bundle, and a 24-hour sepsis management bundle.
Components of Acute Sepsis Bundle
Components of the Sepsis Management Bundle (to be completed in the next 24 hours)
Antimicrobial therapy is strongly recommended to be started as soon as possible after the diagnosis of severe sepsis, or septic shock has been made. Delays in initiating antibiotic therapy have been associated with increased mortality. Recommendations have been made for initiating therapy within 1 hour of diagnosis; however, there appears to be some dispute about the importance of this timing. Despite the observation that mortality from sepsis is not related to the site of infection or the causative organism, including multi-drug resistant organisms, the delay in administering appropriate antibiotics does affect mortality. For this reason, broad-spectrum antibiotics targeting the suspected source are recommended, not necessarily the most appropriate antimicrobial agent.
Obtaining appropriate cultures is intended to influence care after this acute resuscitation phase has already passed. Lots of emphasis has been placed in the past on the timing and technique by which to obtain a blood culture with the greatest likelihood of returning a true positive result. There has been no correlation between the timing of a blood culture draw and detecting significant bacteremia. Recommendations from the Infectious Disease Society of America (IDSA) emphasize drawing them in a sterile manner from at least two different locations, with the volume of the blood cultured being emphasized rather than timing.
Volume Resuscitation, in the acute phase, is recommended as being 30 ml/kg of crystalloid fluids. This fixed number was taken as the average volume of fluid given to patients in the PROCESS, ARISE, and PROMISE trials. The volume of intravenous fluids to give in early resuscitation is still a point of contention and debate, as half of those patients in the study did not receive 30 ml/kg, and half of those patients required more. The ideal fluid to administer is also a contested point, with a general recommendation for "crystalloid fluids" such as normal saline, Ringer's lactate, or plasmalyte from the most recent Surviving Sepsis Campaign guidelines. Recent large trials and reviews on the subject report some benefit with buffered crystalloid solutions (plasmalyte or Ringer’s lactate) over normal saline. The guidelines for treating and managing sepsis do not reflect these findings.
Vasopressors are indicated in septic shock if the condition fails to respond to the intravenous fluid bolus as recommended above. Vasopressors provide additional vascular contraction to assist in maintaining beneficial blood pressure, with a target MAP of greater than 65 mm Hg. Vasopressor choice initially should be norepinephrine, with vasopressin added if norepinephrine after titration dose fails to improve blood pressure by itself. Epinephrine should be used as a second-line agent to norepinephrine. Recommendations at this point are to avoid the use of dopamine except in carefully selected patients. If there is evidence of myocardial dysfunction, recommendations support the addition of a dobutamine infusion to ongoing vasopressor therapy. Vasopressors should be administered through a central venous catheter as soon as placement is possible.
Re-evaluation is critically important to guide the management of these patients after the initial resuscitation period. This typically includes a thorough clinical examination and the concurrent variables of heart rate, blood pressure, urine output, respiratory rate, among others. There have been multiple attempts at clearly defining these goals for acute resuscitation, and have included at different times measuring central venous pressure (CVP), mixed venous oxygen saturation (SvO2), trending lactic acid, stroke volume measurements, mean arterial pressure (MAP), and urine output. CVP measurements have been fraught with imprecision and not found to be useful in predicting whether or not a patient will respond to additional intravenous fluid administration. Mean arterial pressure is the force behind perfusion in the peripheral organs and tissues and should be the goal for both fluid and vasopressor administration. An elevated lactic acid, while not directly a result of tissue perfusion, especially in sepsis, has been directly related to increased mortality. Lactate clearance has also been suggested as a goal for early resuscitation, as a decrease of only 10% in the first 6 hours corresponded to an 11% decrease in the likelihood of mortality, as compared to patients who were unable to achieve this. However, there is weak evidence of a reduction in mortality when lactate guided resuscitation is employed over usual care. For compliance with CMS core measures as noted in the guidelines above, documented reassessment of volume status and tissue perfusion should include vital signs, cardiopulmonary, capillary refill, pulse and skin findings.
The widely held belief that in sepsis tissue hypoxia was the problem led to liberal transfusions of packed red blood cells to increase oxygen delivery in the early years of sepsis management. This, however, has since been disproven with the transfusion requirements in septic shock trial addressing mortality with a lower threshold transfusion of 7 g/dL versus a 9 g/dL. Targeting a lower transfusion threshold of 7 g/dL in septic patients is the current recommendation unless there are signs of critical coronary disease, myocardial ischemia, or acute hemorrhage.
Corticosteroids have 2 important implications in severe sepsis and septic shock, namely that they have anti-inflammatory activity and that they magnify the vaso-constricting response to catecholamines. The conflicting support for the routine use for steroids in severe sepsis and septic shock have led to inconsistent recommendations for its use, despite more than 50 years of trials looking at its benefit in septic shock. Recently the CORTICUS and ADRENAL trials, focusing on this point have failed to show a direct mortality benefit. However, there was a decreased length of ICU stay and days on vasopressors in survivors. The APROCCHSS trial, in contrast, looking at a fludrocortisone and hydrocortisone combination did show a mortality benefit in septic shock patients without an increase in adverse events. Currently, the recommendations support its use in refractory septic shock that has not responded to intravenous fluids and vasopressor therapy as well a low dose prolonged course should be continued while the patient is on vasopressor therapy. Hydrocortisone is the preferred corticosteroid because of its mineralocorticoid effects.
Mechanical ventilation is an important component of management as the respiratory system, predominantly the lungs, are the most commonly affected organ in severe sepsis and septic shock. In the event the patient experiences acute lung injury that progresses to ARDS requiring mechanical ventilation, a lung protective strategy is needed. In the landmark ARDSNet trial, patients who were receiving mechanical ventilation and had developed ARDS had lower mortality and decreased ventilator dependent days with a lung protective strategy. This strategy employed a lower tidal volume strategy of 6 ml/kg of predicted body weight and kept plateau pressures under 30 cm H2O.
Targeted treatments at different intersections in the newer models of sepsis have been continually developed and usually have been unsuccessful at providing any mortality benefit routinely. Drotrecogin alfa, which is recombinant human activated protein C, was approved by the FDA in 2001 and was thought to promote fibrinolysis and inhibit thrombosis which would have a significant impact on the pro-inflammatory state and complications involved in sepsis and septic shock. This was not the case as it was withdrawn from the market after further studies were published showing no benefit and potentially worse outcomes. Further efforts were made to look at the administration of monoclonal antibodies against TNF, blocking IL-1 activity, granulocyte colony-stimulating factor (filgrastim), NO inhibitors, anti-thrombin, N-acetylcysteine, and using antibodies to endotoxin; however, these too failed to demonstrate efficacy. Despite these failures, further development of other immunomodulating agents and the proposed "metabolic cocktail" continue to be pursued, as mortality even with newer therapies remains unacceptably high.
Severe Inflammatory States
Although morbidity and mortality from sepsis have declined in the last 2 decades considerably there remains a large need for improvement in management. This decline in mortality associated with sepsis can be in part attributed to earlier recognition and intervention, as well as advances in understanding of this disease process. Important markers for disease severity and prognostic implications, such as the SIRS or qSOFA criterion, have been able to provide some framework for treatment as well as insight into prognosis for affected patients. Goal-directed therapies that have contributed to this decline in mortality are geared towards goals that have significant prognostic implications. For example, lactic acid accumulation in the setting of sepsis has been shown to be highly specific for predicting the acute phase of death and in-hospital mortality as it increases with levels greater than 4 mmol/L having a 28.4% likelihood of mortality. Although using lactate to guide therapy has not been shown to independently affect mortality in these patients, 2-hour lactate clearance has been shown to be an independent predictor of in-hospital mortality. With the implementation of bundle based care, retrospective studies have also shown greater in-hospital mortality when compared to times to the administration of broad-spectrum antibiotics and completion of a 3-hour bundle. This has some prognostic value attached to it as completion of the intravenous fluid bolus was not shown to affect mortality. Clinical scores such as the qSOFA and SIRS scores have been able to be applied in early settings with worsening scores corresponding to greater in hospital mortality. For patients requiring ICU level care, the SOFA score has been shown to be the best predictor for in-hospital mortality. Using the prognostic implications from these clinical scores can help with discussing goals of care as recommended by recent Surviving Sepsis Campaign guidelines.
The large majority of clinical trials and interventions involving sepsis and septic shock address relatively short-term outcomes, typically 28 day in-hospital mortality. Long-term mortality data with respect to many of the interventions already discussed above, is lacking. Mortality following hospitalization from sepsis is high with rates reported around 31% in the first year and nearing 43% by year 2. Recognized long-term complications of patients with sepsis include critical illness weakness, delirium and acute lung injury, which have a greater impact on morbidity and mortality outside of the first 28 days. Other investigations into late predictors of mortality suggest a pro-inflammatory state of accelerated atherosclerosis and chronic immunosuppression that also contributes to the high mortality rate seen in these patients. Despite advances in sepsis management resulting in an improvement in short-term mortality, prognosis for patients surviving sepsis still remains poor with overall mortality rates remaining seemingly unaffected.
Over 100 years of data show improved patient outcomes, regardless of the disease process, when healthcare professionals collaborate, acting as an interprofessional team. The treatment and management of sepsis and septic shock, especially as the condition progresses, involves nearly every aspect of healthcare. With the implementation of bundled care, communication between physicians, nursing staff, respiratory therapists, and pharmacists becomes more important as these interventions must be implemented swiftly and correctly. With later identification of sepsis resulting in increased morbidity and mortality, emphasis on earlier recognition algorithms has been studied in multiple, interprofessional trials. In one such trial using ancillary staff and then emergency nursing staff in the early identification of sepsis, there was an increased staff knowledge of sepsis, decreased emergency department length of stay, and a statistically significant decrease in mortality. Other similar studies showed a greater distribution of responsibility in the management of these complex patients from physicians to respiratory therapists and nursing staff showing improved patient outcomes. Like treatment, management, and rapid identification of sepsis all play a role in successful patient outcomes, the emphasis on education involving an interprofessional team has increased as well.
Multiple curriculums and recommendations for addressing the development of these interprofessional teams have been put forth, and typically focus on fluid resuscitation, empiric antibiotics, and vasopressor therapy. Developing a successful strategy for managing and treating a complex disease process, such as sepsis, requires an interprofessional team approach. (Level II)
|||Singer M,Deutschman CS,Seymour CW,Shankar-Hari M,Annane D,Bauer M,Bellomo R,Bernard GR,Chiche JD,Coopersmith CM,Hotchkiss RS,Levy MM,Marshall JC,Martin GS,Opal SM,Rubenfeld GD,van der Poll T,Vincent JL,Angus DC, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23 [PubMed PMID: 26903338]|
|||Majno G, The ancient riddle of sigma eta psi iota sigma (sepsis). The Journal of infectious diseases. 1991 May [PubMed PMID: 2019770]|
|||Funk DJ,Parrillo JE,Kumar A, Sepsis and septic shock: a history. Critical care clinics. 2009 Jan [PubMed PMID: 19268796]|
|||Angus DC,van der Poll T, Severe sepsis and septic shock. The New England journal of medicine. 2013 Nov 21 [PubMed PMID: 24256390]|
|||Bone RC,Balk RA,Cerra FB,Dellinger RP,Fein AM,Knaus WA,Schein RM,Sibbald WJ, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun [PubMed PMID: 1303622]|
|||Rivers E,Nguyen B,Havstad S,Ressler J,Muzzin A,Knoblich B,Peterson E,Tomlanovich M, Early goal-directed therapy in the treatment of severe sepsis and septic shock. The New England journal of medicine. 2001 Nov 8 [PubMed PMID: 11794169]|
|||Dellinger RP,Carlet JM,Masur H,Gerlach H,Calandra T,Cohen J,Gea-Banacloche J,Keh D,Marshall JC,Parker MM,Ramsay G,Zimmerman JL,Vincent JL,Levy MM, Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Critical care medicine. 2004 Mar [PubMed PMID: 15090974]|
|||Rhodes A,Evans LE,Alhazzani W,Levy MM,Antonelli M,Ferrer R,Kumar A,Sevransky JE,Sprung CL,Nunnally ME,Rochwerg B,Rubenfeld GD,Angus DC,Annane D,Beale RJ,Bellinghan GJ,Bernard GR,Chiche JD,Coopersmith C,De Backer DP,French CJ,Fujishima S,Gerlach H,Hidalgo JL,Hollenberg SM,Jones AE,Karnad DR,Kleinpell RM,Koh Y,Lisboa TC,Machado FR,Marini JJ,Marshall JC,Mazuski JE,McIntyre LA,McLean AS,Mehta S,Moreno RP,Myburgh J,Navalesi P,Nishida O,Osborn TM,Perner A,Plunkett CM,Ranieri M,Schorr CA,Seckel MA,Seymour CW,Shieh L,Shukri KA,Simpson SQ,Singer M,Thompson BT,Townsend SR,Van der Poll T,Vincent JL,Wiersinga WJ,Zimmerman JL,Dellinger RP, Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive care medicine. 2017 Mar [PubMed PMID: 28101605]|
|||Spiegel R,Farkas JD,Rola P,Kenny JE,Olusanya S,Marik PE,Weingart SD, The 2018 Surviving Sepsis Campaign's Treatment Bundle: When Guidelines Outpace the Evidence Supporting Their Use. Annals of emergency medicine. 2018 Aug 30 [PubMed PMID: 30193754]|
|||Friedman G,Silva E,Vincent JL, Has the mortality of septic shock changed with time. Critical care medicine. 1998 Dec [PubMed PMID: 9875924]|
|||Novosad SA,Sapiano MR,Grigg C,Lake J,Robyn M,Dumyati G,Felsen C,Blog D,Dufort E,Zansky S,Wiedeman K,Avery L,Dantes RB,Jernigan JA,Magill SS,Fiore A,Epstein L, Vital Signs: Epidemiology of Sepsis: Prevalence of Health Care Factors and Opportunities for Prevention. MMWR. Morbidity and mortality weekly report. 2016 Aug 26 [PubMed PMID: 27559759]|
|||Dantes RB,Epstein L, Combatting Sepsis: A Public Health Perspective. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Sep 28 [PubMed PMID: 29846544]|
|||Rhee C,Dantes R,Epstein L,Murphy DJ,Seymour CW,Iwashyna TJ,Kadri SS,Angus DC,Danner RL,Fiore AE,Jernigan JA,Martin GS,Septimus E,Warren DK,Karcz A,Chan C,Menchaca JT,Wang R,Gruber S,Klompas M, Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. JAMA. 2017 Oct 3 [PubMed PMID: 28903154]|
|||Rivers EP,Katranji M,Jaehne KA,Brown S,Abou Dagher G,Cannon C,Coba V, Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva anestesiologica. 2012 Jun [PubMed PMID: 22447123]|
|||Okorie ON,Dellinger P, Lactate: biomarker and potential therapeutic target. Critical care clinics. 2011 Apr [PubMed PMID: 21440203]|
|||Nguyen HB,Rivers EP,Knoblich BP,Jacobsen G,Muzzin A,Ressler JA,Tomlanovich MC, Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Critical care medicine. 2004 Aug [PubMed PMID: 15286537]|
|||Parmar A,Langenberg C,Wan L,May CN,Bellomo R,Bagshaw SM, Epidemiology of septic acute kidney injury. Current drug targets. 2009 Dec [PubMed PMID: 19715542]|
|||Kosaka J,Lankadeva YR,May CN,Bellomo R, Histopathology of Septic Acute Kidney Injury: A Systematic Review of Experimental Data. Critical care medicine. 2016 Sep [PubMed PMID: 27058465]|
|||Iskander KN,Osuchowski MF,Stearns-Kurosawa DJ,Kurosawa S,Stepien D,Valentine C,Remick DG, Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiological reviews. 2013 Jul [PubMed PMID: 23899564]|
|||Zahar JR,Timsit JF,Garrouste-Orgeas M,Français A,Vesin A,Descorps-Declere A,Dubois Y,Souweine B,Haouache H,Goldgran-Toledano D,Allaouchiche B,Azoulay E,Adrie C, Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Critical care medicine. 2011 Aug [PubMed PMID: 21516036]|
|||Serafim R,Gomes JA,Salluh J,Póvoa P, A Comparison of the Quick-SOFA and Systemic Inflammatory Response Syndrome Criteria for the Diagnosis of Sepsis and Prediction of Mortality: A Systematic Review and Meta-Analysis. Chest. 2018 Mar [PubMed PMID: 29289687]|
|||Freund Y,Lemachatti N,Krastinova E,Van Laer M,Claessens YE,Avondo A,Occelli C,Feral-Pierssens AL,Truchot J,Ortega M,Carneiro B,Pernet J,Claret PG,Dami F,Bloom B,Riou B,Beaune S, Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department. JAMA. 2017 Jan 17 [PubMed PMID: 28114554]|
|||Yealy DM,Kellum JA,Huang DT,Barnato AE,Weissfeld LA,Pike F,Terndrup T,Wang HE,Hou PC,LoVecchio F,Filbin MR,Shapiro NI,Angus DC, A randomized trial of protocol-based care for early septic shock. The New England journal of medicine. 2014 May 1 [PubMed PMID: 24635773]|
|||Peake SL,Delaney A,Bailey M,Bellomo R,Cameron PA,Cooper DJ,Higgins AM,Holdgate A,Howe BD,Webb SA,Williams P, Goal-directed resuscitation for patients with early septic shock. The New England journal of medicine. 2014 Oct 16 [PubMed PMID: 25272316]|
|||Mouncey PR,Osborn TM,Power GS,Harrison DA,Sadique MZ,Grieve RD,Jahan R,Tan JC,Harvey SE,Bell D,Bion JF,Coats TJ,Singer M,Young JD,Rowan KM, Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock. Health technology assessment (Winchester, England). 2015 Nov [PubMed PMID: 26597979]|
|||Sterling SA,Miller WR,Pryor J,Puskarich MA,Jones AE, The Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Critical care medicine. 2015 Sep [PubMed PMID: 26121073]|
|||Seymour CW,Gesten F,Prescott HC,Friedrich ME,Iwashyna TJ,Phillips GS,Lemeshow S,Osborn T,Terry KM,Levy MM, Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. The New England journal of medicine. 2017 Jun 8 [PubMed PMID: 28528569]|
|||Riedel S,Bourbeau P,Swartz B,Brecher S,Carroll KC,Stamper PD,Dunne WM,McCardle T,Walk N,Fiebelkorn K,Sewell D,Richter SS,Beekmann S,Doern GV, Timing of specimen collection for blood cultures from febrile patients with bacteremia. Journal of clinical microbiology. 2008 Apr; [PubMed PMID: 18305133]|
|||Finfer S,Myburgh J,Bellomo R, Intravenous fluid therapy in critically ill adults. Nature reviews. Nephrology. 2018 Sep [PubMed PMID: 30072710]|
|||Semler MW,Self WH,Rice TW, Balanced Crystalloids versus Saline in Critically Ill Adults. The New England journal of medicine. 2018 May 17 [PubMed PMID: 29768150]|
|||Asfar P,Meziani F,Hamel JF,Grelon F,Megarbane B,Anguel N,Mira JP,Dequin PF,Gergaud S,Weiss N,Legay F,Le Tulzo Y,Conrad M,Robert R,Gonzalez F,Guitton C,Tamion F,Tonnelier JM,Guezennec P,Van Der Linden T,Vieillard-Baron A,Mariotte E,Pradel G,Lesieur O,Ricard JD,Hervé F,du Cheyron D,Guerin C,Mercat A,Teboul JL,Radermacher P, High versus low blood-pressure target in patients with septic shock. The New England journal of medicine. 2014 Apr 24 [PubMed PMID: 24635770]|
|||Holst LB,Haase N,Wetterslev J,Wernerman J,Guttormsen AB,Karlsson S,Johansson PI,Aneman A,Vang ML,Winding R,Nebrich L,Nibro HL,Rasmussen BS,Lauridsen JR,Nielsen JS,Oldner A,Pettilä V,Cronhjort MB,Andersen LH,Pedersen UG,Reiter N,Wiis J,White JO,Russell L,Thornberg KJ,Hjortrup PB,Müller RG,Møller MH,Steensen M,Tjäder I,Kilsand K,Odeberg-Wernerman S,Sjøbø B,Bundgaard H,Thyø MA,Lodahl D,Mærkedahl R,Albeck C,Illum D,Kruse M,Winkel P,Perner A, Lower versus higher hemoglobin threshold for transfusion in septic shock. The New England journal of medicine. 2014 Oct 9 [PubMed PMID: 25270275]|
|||Sprung CL,Annane D,Keh D,Moreno R,Singer M,Freivogel K,Weiss YG,Benbenishty J,Kalenka A,Forst H,Laterre PF,Reinhart K,Cuthbertson BH,Payen D,Briegel J, Hydrocortisone therapy for patients with septic shock. The New England journal of medicine. 2008 Jan 10 [PubMed PMID: 18184957]|
|||Venkatesh B,Finfer S,Cohen J,Rajbhandari D,Arabi Y,Bellomo R,Billot L,Correa M,Glass P,Harward M,Joyce C,Li Q,McArthur C,Perner A,Rhodes A,Thompson K,Webb S,Myburgh J, Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. The New England journal of medicine. 2018 Mar 1 [PubMed PMID: 29347874]|
|||Annane D,Renault A,Brun-Buisson C,Megarbane B,Quenot JP,Siami S,Cariou A,Forceville X,Schwebel C,Martin C,Timsit JF,Misset B,Ali Benali M,Colin G,Souweine B,Asehnoune K,Mercier E,Chimot L,Charpentier C,François B,Boulain T,Petitpas F,Constantin JM,Dhonneur G,Baudin F,Combes A,Bohé J,Loriferne JF,Amathieu R,Cook F,Slama M,Leroy O,Capellier G,Dargent A,Hissem T,Maxime V,Bellissant E, Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. The New England journal of medicine. 2018 Mar 1 [PubMed PMID: 29490185]|
|||Brower RG,Matthay MA,Morris A,Schoenfeld D,Thompson BT,Wheeler A, Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The New England journal of medicine. 2000 May 4 [PubMed PMID: 10793162]|
|||Marik PE,Khangoora V,Rivera R,Hooper MH,Catravas J, Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017 Jun [PubMed PMID: 27940189]|
|||Raith EP,Udy AA,Bailey M,McGloughlin S,MacIsaac C,Bellomo R,Pilcher DV, Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit. JAMA. 2017 Jan 17 [PubMed PMID: 28114553]|
|||Lemay AC,Anzueto A,Restrepo MI,Mortensen EM, Predictors of long-term mortality after severe sepsis in the elderly. The American journal of the medical sciences. 2014 Apr [PubMed PMID: 23689053]|
|||Winters BD,Eberlein M,Leung J,Needham DM,Pronovost PJ,Sevransky JE, Long-term mortality and quality of life in sepsis: a systematic review. Critical care medicine. 2010 May [PubMed PMID: 20308885]|
|||Kennelly PJ,Martin-Loeches I, Long term mortality following sepsis. Annals of translational medicine. 2016 Oct [PubMed PMID: 27827464]|
|||Frenk J,Chen L,Bhutta ZA,Cohen J,Crisp N,Evans T,Fineberg H,Garcia P,Ke Y,Kelley P,Kistnasamy B,Meleis A,Naylor D,Pablos-Mendez A,Reddy S,Scrimshaw S,Sepulveda J,Serwadda D,Zurayk H, Health professionals for a new century: transforming education to strengthen health systems in an interdependent world. Lancet (London, England). 2010 Dec 4 [PubMed PMID: 21112623]|
|||Tedesco ER,Whiteman K,Heuston M,Swanson-Biearman B,Stephens K, Interprofessional Collaboration to Improve Sepsis Care and Survival Within a Tertiary Care Emergency Department. Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association. 2017 Nov [PubMed PMID: 28550958]|
|||Owen JA,Brashers VL,Littlewood KE,Wright E,Childress RM,Thomas S, Designing and evaluating an effective theory-based continuing interprofessional education program to improve sepsis care by enhancing healthcare team collaboration. Journal of interprofessional care. 2014 May [PubMed PMID: 24593326]|
|||Chung HO,Medina D,Fox-Robichaud A, Interprofessional sepsis education module: a pilot study. CJEM. 2016 Mar [PubMed PMID: 26063312]|